Date: November 18-21, 2021  Metro Toronto Convention Center, North Building 255 Front St W The Lift & Co. Expo will be making a comeback in Toronto following a one-year halt. It promises to be better than ever before, offering value to all stakeholders within the cannabis and psychedelics space, from consumers to professionals and business owners. The event builds on Lift & Co.’s previous successful events while taking it a step further. Over 1000 attendees are expected to show up, and over 250 exhibitors have confirmed their participation. This guarantees an opportunity to build brand awareness, explore global expansion opportunities, network, and engage with unique audiences within the cannabis space. At the core of the expo is Lift & Co.’s commitment to education, connection, and growth. The four-day event is structured to provide attendees top-notch educational content, enrich thought leadership from the industry’s brightest minds and create fun and authentic networking opportunities. There will be speakers and panels comprised of key industry professionals and leaders ready to cover the most talked-about industry topics. This four-day event will kick off with the Lift Cannabis Business Conference. Here, top business leaders, innovators, and regulators will share their approaches, opinions, and perspectives on the most critical factors affecting the cannabis business sector. November 19 will feature the Lift Industry Day, an industry-only trade show and presentation day that promises to kick-start in-depth conversations that build relationships, fuel collaborations, and create opportunities. The day will also feature the Lift Psychedelics Business Summit, covering updates on psychedelics research and business intelligence on the four pillars of today’s psychedelic renaissance. Consumer Days will span the last two days of the event. Here, recreational cannabis consumers and medical patients will explore and connect with over 250 exhibitors to learn about the different products and services they offer. There will also be the main stage where speakers and panels will be covering widespread topics in the cannabis industry and answering any questions that attendees might have. The Lift & Co. Expo is currently the largest industry and consumer cannabis event in Canada. It is an opportunity for consumers and professionals within the cannabis and psychedelics space to connect and move the industry forward. It is also an event that showcases the breadth and growth of the Canadian cannabis industry while offering an opportunity for both novices and experts to draw value from key players in this space. For those interested in the event, please purchase their tickets here https://ibn.fm/E1fZx Should you wish to exhibit at the event, you can book a booth here https://ibn.fm/6a1l3

• Cannabis sales are projected to increase as NUGS makes move to increase premium cannabis production
• MOU grants rights for NUGS to purchase 10% of the facility at a valuation of $15 million for the entire facility
• Agreement strengthens company’s status as an emerging leader in the vertically integrated California cannabis marketplace

As sales of high-quality cannabis in California, the largest cannabis market in the country, are projected to increase, Cannabis Strategic Ventures (OTCQB: NUGS) is taking strategic steps to ensure its position in the growing space. Most recently, the company inked a Memorandum of Understanding with Devine Solution Inc. with the end goal of increasing its cannabis production capacity (https://ibn.fm/o3ES3). “Sales of legal adult-use cannabis are expected to increase greatly in the state of California between 2018 and 2024,” reported Statista (https://ibn.fm/He5e7). “Sales already reached 2.5 billion U.S. dollars in 2018 (the largest U.S. market) and are expected to grow to roughly 7.2 billion by 2024.” Cannabis Strategic Ventures is aligning its long-term strategy with that growth in mind, as the company remains focused on shaping the future of the cannabis industry by striving for constant evolution in products, places and people. The MOU outlines NUGS’ plans relating to its proposed acquisition of an indoor cannabis cultivation facility owned by California-based Devine. Based on the terms of the recently signed MOU, NUGS is moving forward to purchase 10% of the facility at a valuation of $15 million for the entire facility; the agreement includes an option to purchase an additional 41% of the facility (which would comprise a controlling 51% stake) at this same valuation, which would results in a controlling 51% stake for Cannabis Strategic Ventures. “This deal represents the potential to sharply increase our premium cannabis production capacity and materially augment our status as an emerging leader in the vertically integrated California cannabis marketplace,” said NUGS CEO Simon Yu. “We have already amassed years of experience refining our cultivation methods and strains in an outdoor framework with our NUGS Farm North site. Adding a top-tier indoor cultivation operation stands to help us further build upon that success and drive more volume in the premium flower market, which has powerful implications given our recent expansion into the dispensary marketplace with our MDRN Tree downtown LA dispensary location. The combination grants NUGS expanding operations at both ends of the farm-to-sale model.” The 15,600-square foot facility is located in Sacramento, California, and has the potential to house an estimated 500 grow lights. The existing infrastructure has the potential to produce up to three pounds of premium exotic cannabis flower per light per harvest, with a projected 5.75 harvests per year. That would mean the potential for more than 7,000 pounds of premium cannabis flower per year for NUGS, which is one of the largest publicly traded marijuana cultivators in the United States. Cannabis Strategic Ventures also has a wholly owned subsidiary — NUGS Farm North — that is a fully state legal licensed Cannabis cultivator in the state of California. The property has more than six acres of greenhouse. Cannabis Strategic Ventures cultivates and sells cannabis biomass and related cannabis products to the legal cannabis market. For more information, visit the company’s website at www.CannabisStrategic.com. NOTE TO INVESTORS: The latest news and updates relating to NUGS are available in the company’s newsroom at http://ibn.fm/NUGS

• Mullen Automotive is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life
• The company commenced trading on the Nasdaq Capital Market on November 5, 2021, following a stock-for-stock merger with Net Element Inc.
• The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (“LAIAS”) on November 17, 2021, is currently open for reservations
• The global EV market is forecast to grow at a CAGR of 22.6% through 2027
• Mullen is led by CEO and Founder David Michery, a seasoned executive with more than 25 years of management, marketing, distressed assets, and business restructuring experience

Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. Commencement of Trading on Nasdaq On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market. “Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.” The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc. The Mullen FIVE The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (“LAIAS”) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban. The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person. Capable of 0-60 in 3.2 seconds with a max speed of 155 mph, the FIVE comes with an estimated range of 325 miles. Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the Zero Emission Vehicle Awards (“ZEVAs”) “People’s Choice” Awards. LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. Additionally, the FIVE will be on display at the Consumer Electronics Show (“CES”) in Las Vegas in January 2022. The company intends to bring the FIVE to market in 2024, and reservations are currently open here. Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high-performance Sports Car, the DragonFLY. Expansion of Manufacturing Capacity On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi. Mullen’s Advanced Manufacturing and Engineering Facility (“AMEC”) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover. On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop. EV Market Outlook The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations. Management Team Mullen is led by an executive team with extensive EV, OEM and, high-growth startup experience. David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision. Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America. Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars. For more information, visit the company’s website at www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

• Mydecine has filed a technology patent application that allows for the creation of nanoemulsion-empowered formulations to improve, stabilize, and increase the bioavailability of ingredients
• The company aims to use the nanoemulsion technology to enhance the bioavailability and optimize the delivery of compounds that are inspired by traditional ingredients
• In September, Mydecine filed its final patent application for MYCO-003, one of its lead drug candidates for enhanced treatment of anxiety and post-traumatic stress disorder
• MYCOF is steadily strengthening its IP portfolio as it seeks to reimagine the treatment of mental health and addiction

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), an emerging biotechnology and digital company dedicated to efficiently developing first- and second-generation novel therapeutics to treat PTSD, addiction, and other mental health disorders, has achieved a significant milestone for its drug development pipeline. The Denver-based company recently filed a technology patent application that will cover as well as allow for the creation of formulations that use nanoemulsion technology to improve, stabilize, increase bioavailability, and make repeatable properties of ingredients from traditional medicines. The formulations to be covered by the patent are Generally Recognized as Safe (“GRAS”) – an FDA certification that designates that a food substance or chemical additive is considered safe by experts (https://ibn.fm/WYhxm). An advanced drug delivery system, nanoemulsion has the potential of improving the bioavailability of multiple active pharmaceutical ingredients (“APIs”). In addition, it offers enhanced stability, fast digestibility, controlled release, and protection against degradation (https://ibn.fm/wLgMH). Specifically, Mydecine is targeting the enhanced bioavailability and controlled release capabilities of the nanoemulsion technology. The system’s controlled-release capability, for example, will be instrumental in the company’s active drug development by aiding in micro-dosing and customizing dosages. Similarly, Mydecine’s GRAS-pending formulations will provide an opportunity to enhance the bioavailability of natural compounds found in traditional medicine, including reishi and cordyceps, allowing them to be added to a growing variety of consumer products to achieve improved benefits. “By fine-tuning our ingredients and extraction processes, we are able to deliver these valuable properties more accurately and effectively to consumers,” said Rob Roscow, the Chief Science Officer at MYCOF. On his part, CEO Josh Bartch noted that the patent application had introduced an additional wall of IP protection that covers vital technologically innovative properties of compounds that can empower multiple over-the-counter (“OTC”) supplements and consumer products. “The compatibility of these formulas as patent-protected ingredients has Mydecine excited to develop a wide variety of licensing opportunities,” Josh added. “As we continue to produce new methods to traditional medicinal roots, it is critical that we apply layerable patented technology to our discovery process in order to enhance the use of extracts and take advantage of increasing demand for these valuable compounds in today’s health treatments.” In addition to continuing with the development of compounds inspired by traditional ingredients but empowered by modern nanoemulsion technology to enhance bioavailability and optimize delivery to users, Mydecine also intends to use the same technology in OTC consumer products to improve usability and accessibility. Notably, the recent technology patent filing follows on the heels of a September 22 announcement that Mydecine filed its final patent application with the United States Patent and Trademark Office (“USPTO”) and the World Intellectual Property Organization (“WIPO”) for MYCO-003, one of its lead drug candidates. MYCO-003 is a psilocybin formulation developed to offer enhanced treatment of post-traumatic stress disorder (“PTSD”) and anxiety (https://ibn.fm/Uujxl). Committed to finding answers to mental health challenges, Mydecine has submitted multiple pending patents for novel innovation in first- and second-generation drugs and compounds. Through its latest technology patent filing, coupled with the September final patent application, the company is steadily strengthening its intellectual property (“IP”) portfolio as it seeks to reimagine mental health and addiction treatment with safer, more effective solutions. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• PlantX has opened its first United States brick and mortar store in the Hillcrest neighborhood of San Diego, although the company’s earlier acquisition of New Deli, a vegan marketplace opened by Chef Matthew Kenney, resulted in a rebranding of their Venice, California New Deli location as XMarket
• The partnership between PlantX and Kenney reflects a mission to educate consumers and the public about living a plant-based/vegan lifestyle by offering educational resources in the form of blogs, podcasts, and YouTube videos
• PlantX features products ranging from food, beverages, pets, personal hygiene, and more, and the company’s XMarket locations also offer local delivery options via Uber Eats
• The company is now working on opening XMarket locations in Hudson’s Bar stores in Toronto and Ottawa, along with an opening in Tel Aviv, Israel

Described as the “vegan Amazon,” PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has opened its first United States brick and mortar establishment, XMarket, in San Diego’s Hillcrest neighborhood, following an earlier rebranding of an acquired location in Venice, California as XMarket. According to Alex Hoffman, CMO of PlantX, the company’s next location will be in Tel Aviv, Israel, followed by two locations opening up inside Hudson’s Bay stores in Ottawa (Rideau), and Toronto (Yorkdale). “A few other locations are on our radar, but nothing finalized yet,” Hoffman added. The company plans to take plant-based and vegan living worldwide – providing resources and educational materials to those interested in the benefits. According to Kenney, the goal of the partnership with Plantx is to “educate and provide more people access to a plant-based lifestyle”, adding that “Along with our retail and ecommerce initiatives, we are committed to investing in and developing innovative products that bring a sustainable and healthful change to the culinary landscape” (https://ibn.fm/rXHYU). PlantX, much like Kenney, aims to redefine the plant-based community through e-commerce, becoming a trusted name for people living plant-based lives. As an e-commerce marketplace, PlantX offers:

• An array of plant-based grocery items
• Meal delivery with recipes created by renowned plant-based chefs from around the world
• Plant shop – delivers to homes across the United States and Canada
• Easy to follow weekly plant-based recipes
• Partnership with prominent vegan/plant-based community figures
• A community of like-minded individuals

As for XMarket, the shelves are lined with a large selection of vegan and plant-based products. The store also offers local vegan business products, including Kula Ice Cream, Tracy’s Real Food, and San Diego Tempeh soy-free proteins. There is also an open-air vegan café that serves Unity Coffee cappuccinos, oat milk lattes, and cups of steeped Brandywine Coffee Roasters teas. These drinks pair nicely with the pastries from Pan el Barro, The Gluten Free Baking Co., and Yvonne’s Vegan Kitchen. PlantX and XMarket are devoted to providing patrons with the proper educational materials – allowing them to determine if a plant-based/vegan lifestyle is right for them. XMarket offers visiting patrons educational literature that has been included around the market space, including recipe cards, plant care notes, and prominently displayed nutritional information. The staff at the market has also completed training by nutritionist Kelly Irwin and is prepared to answer any questions the public may have while shopping. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• International cannabis cultivator, manufacturer, and distributor of plant-based lifestyle and wellness brands Flora Growth Corp. is steadily building a worldwide pipeline for downstream cannabis brands using its Colombian cultivation facilities and a growing list of trade partners
• Flora Growth recently announced multiple distribution and e-commerce marketplace agreements that will see its two leading skincare brands, MIND Naturals and Awe (Ô), distributed via GlossWire and Showfields
• The company also expects its Colombian on-site CBD extraction facility to come online as well as complete the first harvests of its high-THC psychoactive cultivars later in the month
• Flora Growth achieved Good Agricultural and Collection Practices (“GACP”) certification from the international medical cannabis standard-setter Control Union Medical Cannabis Standard (“CUMCS”) last month, which paves the way for international sales

A leading global cannabis cultivator and manufacturer of products and brands in CPG, fashion, food, and inhalation technology Flora Growth (NASDAQ: FLGC) is building an international pipeline for downstream cannabis products that begins with its cultivation facilities in Colombia’s ideal climate and ends with commercial outlets in nations ranging across the Americas, to the European Union, all the way around the world to Australia. The company announced an e-commerce agreement with SHOWFIELDS on Oct. 27, with GlossWire’s digital beauty marketplace Oct. 28 (https://ibn.fm/7Z3KI), and certification by international medical cannabis standards setter Control Union Medical Cannabis Standard (“CUMCS”) on Oct. 25 (https://ibn.fm/7VpGw). Flora Growth is preparing to fire up operation of its new onsite cannabis extraction facility in mid-November, located on-site at the company’s 100-hectare (247 acres) Cosechemos cultivation base in central Colombia. This development will complement its operational Flora Labs facility located in Bogotá that boasts a modern 16,000-square-ft manufacturing footprint and holds multiple GMP certifications with a diversified portfolio with over 190 products and 63 OTC products registered and licensed with INVIMA (FDA-equivalent in Colombia). Recent regulatory changes enacted by Colombia’s government have made it possible for companies such as Flora Growth to export dried cannabis flower and extracts used in pharmaceuticals and nutraceuticals in the food, beverage, cosmetics, and textiles markets without running afoul of the country’s drug interdiction efforts. Cannabis derivatives in the pharmaceutical and nutraceutical markets have gained acceptance worldwide in recent years, as well as the push towards legalization for adult-use in many jurisdictions around the world. Prohibition Partners’ own predictive outlook states the United Kingdom’s cannabis sector will see revenues growing to as much as $4.3 billion, North America’s to $47.3 billion, and the larger international market’s to $103.9 billion by 2024, showcasing the explosive expectations of international demand (https://ibn.fm/maOvd). Flora Growth’s deal with SHOWFIELDS and GlossWire will launch sales of Flora’s two skincare brands, MIND Naturals and Awe (Ô) and is expected to greatly enhance brand awareness in the United States. The marketplaces feature e-commerce interaction over “a highly curated mix of emerging and established brands that are making an impact in the beauty and grooming spaces,” according to the GlossWire announcement. “This unique intersection of tech and beauty allows for discovery, storytelling, and a deeper understanding of the customer,” Flora Growth President and CEO Luis Merchan stated, highlighting new emerging responsiveness to consumer trends and feedback. Flora reports it is achieving plant yields 40 to 60 percent higher than the company originally expected at its Cosechemos site and that it expects to harvest an initial crop of high-tetrahydrocannabinol (“THC”) psychoactive plant cultivars this month. The company is working on the pre-audit process for gaining good manufacturing practice (“GMP”) status with the European Union for the Cosechemos facility’s products and has also partnered with Hoshi International Inc. to provide another pathway to Europe. “The primary focus at Cosechemos this year has been optimizing and scaling our cultivation and processing activities while working closely with regulatory bodies and agencies to be granted our GACP certification (from CUMCS) so that we can commercially distribute our medical-grade cannabis products internationally,” VP of Agriculture Javier Franco stated in the Oct. 25 news release. “This further establishes our commitment to operational excellence and transparency, as well as our commitment to producing high-quality, consistent cannabis products to serve the global cannabis markets.” For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and it’s most ambitious yet
• This study builds on the HYPER-H21-1 and HYPER-H21-2 findings, as well as the HYPER-H21-3 study that is set to begin dosing in mid-November 2021
• Lexaria’s goal is to pursue regulatory approval for its proprietary DehydraTECH-CBD for potential use as a treatment for high blood pressure
• Study protocols are being readied for submission to the IRB, and approval is expected by January 2022

Lexaria Bioscience (NASDAQ: LEXX) has, so far in 2021, embarked on several studies geared towards evaluating its proprietary DehydraTECH(TM) CBD for the potential treatment of hypertension and heart disease. Results from the first hypertension study, HYPER-H21-1, were released on July 29, 2021, showing that the administration of a single dose of 300 mg of DehydraTECH-CBD resulted in a significant reduction in blood pressure from baseline. Of the 24 adult volunteers in the study, those who were Stage 2 hypertensive, peak systolic blood pressure reductions from baseline were observed of as much as approximately 13 mmHg by the 50-minute time point with DehydraTECH-CBD. Additionally, systolic blood pressure remained depressed throughout almost the entire 3-hour duration of the study (https://ibn.fm/DENxV). The second study of the year, HYPER-H21-2, also yielded more impressive results. Again, 16 adult volunteers took part in the study, which involved taking three doses of 150 mg each of DehydraTECH-CBD, with results measured over a 24-hr ambulatory period. At selected times during the study, volunteers with mild to moderate hypertension averaged as much as a 20 mmHg decrease in blood pressure, relative to placebo, coupled with an average 7% reduction in systolic pressure. The learnings from these two studies have led up to the HYPER-H21-4 clinical study, Lexaria’s most ambitious one thus far. It is expected to involve 60 different volunteers aged between 45 and 70 years. Each of them will use three 150 mg doses of DehydraTECH-CBD every day over six weeks. “HYPER-H21-4 is the most ambitious study Lexaria has ever undertaken and is enabled from the successful outcomes from our other 2021 human hypertension studies,” noted Chris Bunka, Lexaria’s Chief Executive Officer (“CEO”). This study will use a double-blinded, randomized cross-over design while also utilizing a placebo control. A specific group of volunteers will already be using leading standard care hypertension drugs to evaluate the efficacy of the patented DehydraTECH technology, particularly, DehydraTECH-CBD with and without other hypertension treatments. The HYPER-H21-4 study will be more comprehensive than Lexaria’s previous studies. The eventual goal is to seek regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure, and data from this study could be instrumental in that pursuit. Different types of analysis will be conducted, from 24-hour ambulatory blood pressure to autonomic balance and arterial stiffness, brain structure and function through magnetic resonance imaging and blood biomarkers including lipids such as cholesterol and more. Study protocols for this study are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. In the meantime, Lexaria has completed DehydraTECH-CBD manufacturing for the HYPER-H21-3 study. Clinical test articles have also been delivered to the study location. Dosing is set to begin in mid-November or thereabouts and will be completed by mid-December. Blood pressure findings will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4 study as well. Today, about 1.28 billion people suffer from hypertension, making it one of the world’s top health problems. Of these, only 21% of them have the condition under control, a statistic that demonstrates an enormous unmet need (https://ibn.fm/jUP1F). The hypertension treatment market is valued at USD$28 billion per year, and it is projected that in 2022, the broader cardiovascular disease category, under which hypertension falls, will be valued at USD$146 billion (https://ibn.fm/zVMT9). Lexaria understands the high unmet need for hypertension and cardiovascular diseases in general, hence its investment into its DehydraTECH research and the development of its proprietary DehydraTECH-CBD. With the HYPER-H21-4 study, the company is inching ever closer to regulatory approval, which would allow it to tap into this lucrative market and offer relief to billions of people living with cardiovascular diseases today. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Metro Toronto Convention Center, North Building 255 Front St W The Lift & Co. Expo, Canada’s number one cannabis event, makes a comeback this year in Toronto. This four-day event promises to be better than ever before, all while educating, connecting, and growing cannabis consumers, professionals, and media. This event will feature over 250 exhibitors and different forward-thinking speakers, movers and shakers within the industry. It promises to offer attendees top-notch educational content, enrich thought leadership from the industry’s brightest minds, and present fun and authentic networking opportunities. The four-day event will have the Lift Cannabis Conference on the first day. This conference will be dedicated to Cannabis 2.0 updates, where Canada’s top business leaders, regulators, and innovators will share their perspectives on critical issues affecting Canada’s cannabis business sector. It promises value to new start-ups, those seeking to expand their businesses, or even curious consumers. There will be something for everyone. The second day will feature the Lift Psychedelics Business Summit along with the Lift Industry Day. The Industry Day will serve as an excellent avenue to kick-start in-depth conversations, build networks, spark relationships, create opportunities, and fuel collaborations. The Lift Psychedelics Business Summit, on the other hand, will take a deep dive into psychedelics research and the psychedelics industry. It is structured to offer attendees the most up-to-date business intelligence, specifically on the four pillars of today’s psychedelic renaissance. The last two days of the expo are dubbed “Consumer Days.” Lift & Co. invites all recreational consumers and medical patients to explore, learn and connect with over 250 different exhibitors from Canada and around the world. These consumer days will also feature speakers and panels on the main stage, covering the most talked about topics and answering frequently asked questions about the cannabis industry. Over 200 companies have confirmed their support of the event, which promises to be Canada’s largest industry and consumer cannabis event. Some include Cannabis Prospect Magazine, CAVCM, BioFloral, Indiva, Flush, and BIS Solutions. Thousands of cannabis enthusiasts and business people are also expected to attend in what will be an unmatched opportunity to build their brand awareness, explore global expansion opportunities, network, and engage with unique audiences. All roads lead to Toronto this November for Canada’s number one cannabis event. For those interested in the event, please purchase their tickets here https://ibn.fm/E1fZx Should you wish to exhibit at the event, you can book a booth here https://ibn.fm/6a1l3

• Pharmaceutical company Tryp Therapeutics is developing a proprietary synthetic hallucinogen as potential medical solutions for select unmet health needs, with a focus on taking psychedelic therapeutics beyond mental health
• The company recently attended the Wonderland: Miami where Compass Pathways unveiled highly anticipated data from their Phase 2b trial in treatment-resistant depression
• Tryp’s Chairman and CEO Greg McKee served on a panel at Wonderland: Miami discussing the potential of synthetic psilocybin in chronic pain indications and the importance of supporting industry wins

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) Chairman and CEO Greg McKee recently participated in Microdose’s Wonderland: Miami conference as a panelist for the “Developing Psychedelic Medicine Beyond What We Already Know” forum exploring the potential of once-taboo substances that are gaining an increasing measure of legitimacy and legal recognition. McKee’s appearance at the Nov. 8 and 9 event billed as “The Largest Psychedelic Medicine Business Event, Ever” gave Tryp an audience that was expected to include participants from a span of up to 140 countries or more in the Sun Belt’s “Magic City,” a world-class hub for trade and tourism. Greg gave an overview of Tryp’s strategy and progress, as well as addressing the crowd in a call to action to continue to emphasize strong support from every angle in order to give psychedelic therapeutic potential the validation it has already proven to deserve. The Compass data provided proof of rapid and durable responses after three weeks of psilocybin dosing and psychotherapy. Tryp has been actively engaged in developing synthetic psychedelic drugs as the newest sought-after solutions in treating chronic pain and other medical conditions with largely unmet needs. These data continue to validate Tryp’s hypothesis, as Tryp continues to progress towards conducting 4 Phase 2a trials evaluating psilocybin and psychotherapy in fibromyalgia, and eating disorder, pending a favorable review by the FDA. The company’s submission of an Investigational New Drug application to the U.S. Food and Drug Administration (“FDA”) for its TRP-8802 clinical candidate (https://ibn.fm/mz1Je) marks the latest advancement in its clinical trial that will initially evaluate 25mg oral psilocybin drug candidate, provided by Usona Institute. Compass Pathway’s data revealed the highest response rate among the 25mg dosing cohort, which provides further support for Tryp’s upcoming trial, and Tryp’s trademarked drug candidate, TRP-8803. TRP-8803 will be a synthetic psilocybin drug candidate in which the Company is completing preclinical and bridging studies to perfect its novel route of administration that will lead to more precise control over the patient’s psychedelic experience during the treatment. Tryp expects to complete a Phase 2a trial for TRP-8802 during the next nine months to determine its safety and initial effectiveness among patients with fibromyalgia. Similarly, TRP-8802 will be evaluated for its performance in treating phantom limb pain and complex regional pain syndrome (“CRPS”). Additional testing in select eating disorders is expected soon pending further review from the FDA. The clinical trials will be run in combination with psychotherapists trained by Fluence Training. The company has developed a novel method of administering TRP-8803 to make the experience better for patients. Although testing is still in the pre-clinical stage for it, Tryp expects to benefit from data produced in the TRP-8802 trials as well as data derived directly from TRP-8803 to advance it to phase 2b testing within the next 18 months and on to eventual commercialization. Tryp is committed to driving clinical progress and doing its part to continue to validate the use of psilocybin in select chronic diseases. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Ammonia is currently the second most produced chemical
• Its production, which accounts for 2% of the world’s fossil fuel use, currently generates over 420 million tons of CO2 annually
• With the growing global population, the demand for nitrogen for fertilizer is increasing, and with it comes an increase in CO2 production
• Ammonia supply out of the Black Sea region has dropped, with natural gas, the primary feedstock for ammonia production, expected to reach a long-time high of US$1,000/mt
• FuelPositive seeks to capitalize on the growing need for access to fertilizer and a dwindling ammonia supply chain with its on-site green ammonia production systems

According to the United Nations, the world population is projected to reach 9.8 billion in 2050, and 11.2 billion in 2100 (https://ibn.fm/yXNLi). This population growth will put a strain on global food supplies and productivity – but it will also significantly increase the global demand for nitrogen for fertilizer. While the farming sector has benefitted from innovations such as genetically-modified crops and AI-driven agriculture to boost crop yields, the primary need for most of the world is simply greater access to fertilizer as opposed to these other innovations. FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) has pioneered a clean energy solution in the form of green ammonia for various applications, including fertilizer for the agriculture sector. Ammonia’s chemical name is NH3. In the agriculture sector, it is primarily the “N” or nitrogen that plays a key role because it is necessary for the healthy growth of crops. But the “H”, which stands for hydrogen, is equally important. With its proprietary system, FuelPositive can store hydrogen in its green ammonia, allowing it to be efficiently used for energy storage and as fuel for internal combustion engine vehicles. When used properly, as fertilizer or as a fossil fuel replacement, the only discernable emissions from its carbon-free green ammonia is water vapor, or, in the case of fertilizer, some hydrogen emissions which are completely inert. (Nitrous oxide which is created when ammonia is burned, can be eliminated with proper combustion or by using catalytic convertors in internal combustion engines.) Most importantly, the use of FuelPositive’s green ammonia in agriculture will result in a significant reduction in CO2 emissions, a critical benefit, considering how food production contributes to global warming worldwide. Ammonia currently ranks as the second most produced chemical globally, with production accounting for 2% of the world’s fossil fuel use. The industry, as a whole, generates over 420 million tons of CO2 annually, creating a challenging tension between producing much-needed fertilizer to meet our needs for food and reducing carbon emissions (https://ibn.fm/T6chL). FuelPositive’s green ammonia technology provides an innovative solution to growing environmental concerns. It also addresses another important challenge: centralization of ammonia production. For most companies in this sector, operating at scale in massive centralized production facilities increases ammonia output, reducing the gap between supply and demand. However, this centralization results in a precarious supply chain buffeted by fossil fuel shortages, damage to facilities because of extreme weather and even labor shortages. The resulting drop in production and rise in prices causes food shortages, as well as economic hardship for farmers around the world. The Director of New Business Equipment at Mitsubishi Heavy Industries Compressor International Corporation (MCO-I), Clayton Jurica, has reckoned that the solution lies not in choosing larger or smaller plants. Instead, he notes, “There are pockets of demand around the world where transportation or logistics is complicated, so building small to mid-sized ammonia production plants to meet local demand makes economic sense.” FuelPositive’s green ammonia effectively addresses problems associated with scaling and transportation. It requires less energy to produce and is manufactured using a modular, scalable, transportable production system – a “plant in a box” – that is situated where the green ammonia is required. There is no need for massive refineries or a complicated supply chain. The end user simply produces the amount of green ammonia needed using air, water and sustainable electricity. In the case of farms, the farmer would have a FuelPositive production system on the farm, producing fertilizer for their crops, fuel for their farm systems and machinery, and to be used as on-the-farm grid storage for use when other sources of renewable electricity are unavailable. With the recent drop in ammonia supplies out of the Black Sea, FuelPositive’s green ammonia is even more appealing. As of the end of October 2021, delivery from Black Sea refineries into Europe was challenging, given how low gas supplies have become. Some of the trade sources are reportedly out of supply until mid-November, a factor that is driving up the price, which is expected to hit US$1,000 per metric tonne (“MT”) (https://ibn.fm/ksIiL). As it stands, natural gas and coal are the primary feedstocks for ammonia production. However, low pump rates in Russia have made the product even more scarce in the Black Sea, a factor that is further pushing up its price and inhibiting ammonia production in Europe. However, with FuelPositive’s green ammonia, reliance on large amounts of natural gas or coal in ammonia production is not a factor, allowing for a greener yet more reliable method of ammonia production. FuelPositive is looking to capitalize on this dwindling supply of ammonia to push its green alternative, making ammonia more accessible to farmers and contributing to a greener planet, while greatly growing its market share. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF